Loading...
Derniers dépôts
-
Anne Patsouris, Kadija Diop, Olivier Tredan, Daniel Nenciu, Anthony Gonçalves, et al.. Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation. European Journal of Cancer, 2021, 159, pp.283-295. ⟨10.1016/j.ejca.2021.09.028⟩. ⟨hal-04522229⟩
-
Sylvain Legrand, Asma Saifudeen, Hélène Bordelet, Julien Vernerey, Arnaud Guille, et al.. Absence of chromosome axis protein recruitment prevents meiotic recombination chromosome-wide in the budding yeast Lachancea kluyveri. Proceedings of the National Academy of Sciences of the United States of America, 2024, 121 (12), pp.e2312820121. ⟨10.1073/pnas.2312820121⟩. ⟨pasteur-04603593⟩
-
Mihaela Aldea, Arianna Marinello, Michael Duruisseaux, Wael Zrafi, Nicole Conci, et al.. RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion. Journal of Thoracic Oncology, 2023, 18 (5), pp.576-586. ⟨10.1016/j.jtho.2022.12.018⟩. ⟨hal-04519993⟩
-
S. Peters, A. Scherpereel, R. Cornelissen, Y. Oulkhouir, L. Greillier, et al.. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Annals of Oncology, 2022, 33 (5), pp.488-499. ⟨10.1016/j.annonc.2022.01.074⟩. ⟨hal-04085315⟩
-
Quentin Dominique Thomas, Amal Boussere, Jean-Marc Classe, Christophe Pomel, Hélène Costaz, et al.. Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort. Gynecologic Oncology, 2022, 167 (1), pp.11-21. ⟨10.1016/j.ygyno.2022.08.005⟩. ⟨hal-03868125⟩
-
Benjamin Levy, Fabrice Barlesi, Luis Paz-Ares, Jaafar Bennouna, Mustafa Erman, et al.. Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO). LUNG CANCER, 2022, 166, pp.107-113. ⟨10.1016/j.lungcan.2022.01.023⟩. ⟨hal-04085328⟩
-
-
-
Mihaela Aldea, Arianna Marinello, Michael Duruisseaux, Wael Zrafi, Nicole Conci, et al.. RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion. Journal of Thoracic Oncology, 2023, 18 (5), pp.576-586. ⟨10.1016/j.jtho.2022.12.018⟩. ⟨hal-04176638⟩
-
Pauline Marolleau, David Tougeron, Benoit Allignet, Romain Cohen, David Sefrioui, et al.. Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study. International Journal of Cancer, 2023, ⟨10.1002/ijc.34636⟩. ⟨hal-04154476⟩
-
-
Susanne A Gatz, Anne C Harttrampf, Caroline Brard, Francisco Bautista, Nicolas André, et al.. Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial. Clinical Cancer Research, 2023, 30 (4), pp.741 - 753. ⟨10.1158/1078-0432.ccr-23-2959⟩. ⟨inserm-04590103⟩
-
Thierry Lebret, Xavier Paoletti, Géraldine Pignot, Mathieu Roumiguié, Marc C. Colombel, et al.. Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trial. World Journal of Urology, 2023, 41, pp.2381-2388. ⟨10.1007/s00345-023-04519-4⟩. ⟨hal-04195182⟩
-
Gilles Houvenaeghel, Alexandre De Nonneville, Monique Cohen, Jean-Marc Classe, Fabien Reyal, et al.. Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study. European Journal of Cancer, 2022, 176, pp.58-69. ⟨10.1016/j.ejca.2022.08.027⟩. ⟨hal-04084967⟩
-
Jordi Remon, Nicolas Girard, Silvia Novello, Javier de Castro, Laurence Bigay-Game, et al.. PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. Clinical Lung Cancer, 2021, ⟨10.1016/j.cllc.2021.07.008⟩. ⟨hal-03524401⟩
-
Guilhem Roubaud, M. Özgüroğlu, Nicolas Penel, N. Matsubara, N. Mehra, et al.. Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study.. European Journal of Cancer, 2022, European Journal of Cancer, 170, pp.73-84. ⟨10.1016/j.ejca.2022.04.016⟩. ⟨hal-04568938⟩
-
-
-
Mark van Barele, Delal Akdeniz, Bernadette a M Heemskerk-Gerritsen, Nadine Andrieu, Catherine Noguès, et al.. Contralateral breast cancer risk in patients with breast cancer and a germline-BRCA1/2 pathogenic variant undergoing radiation. JNCI: Journal of the National Cancer Institute, 2024, 115, pp.1318 - 1328. ⟨10.1093/jnci/djad116⟩. ⟨inserm-04545755⟩
-
Antoine Verger, T. Horowitz, F. Le Jeune, C. Prunier-Aesh, S. Querellou, et al.. Clinical authorization of amyloid PET in France: Towards a more precise diagnosis of Alzheimer's disease. Médecine Nucléaire - Imagerie Fonctionnelle et Métabolique, 2023, 47 (4), pp.175-178. ⟨10.1016/j.mednuc.2023.03.002⟩. ⟨hal-04415555⟩